Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
J Immunother Cancer. 2022 Jan;10(2). doi: 10.1136/jitc-2021-003534.
Immunotherapy is less effective in patients with epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC). Lower programmed cell death-ligand 1 (PD-L1) expression and tumor mutation burden (TMB) are reported to be the underlying mechanism. Being another important factor to affect the efficacy of immunotherapy, tumor microenvironment (TME) characteristics of this subgroup of NSCLC are not comprehensively understood up to date. Hence, we initiated this study to describe the specific TME of EGFR-mutant lung adenocarcinoma (LUAD) from cellular compositional and functional perspectives to better understand the immune landscape of this most common subtype of NSCLC.
We used single-cell transcriptome sequencing and multiplex immunohistochemistry to investigate the immune microenvironment of EGFR-mutant and EGFR wild-type LUADs and determined the efficacy of immunotherapy. We analyzed single cells from nine treatment-naïve samples and compared them to three post-immunotherapy samples previously reported from single cell perspective using bioinformatics methods.
We found that EGFR-mutant malignant epithelial cells had similar characteristics to the epithelial cells in non-responders. EGFR-mutant LUAD lacked CD8 tissue-resident memory (TRM) cells, which could promote tertiary lymphoid structure generation by secreting CXCL13. In addition, other cell types, including tumor-associated macrophages and cancer-associated fibroblasts, which are capable of recruiting, retaining, and expanding CD8 TRM cells in the TME, were also deficient in EGFR-mutant LUAD. Furthermore, EGFR-mutant LUAD had significantly less crosstalk between T cells and other cell types via programmed cell death-1 (PD-1) and PD-L1 or other immune checkpoints compared with EGFR wild-type LUAD.
Our findings provide a comprehensive understanding of the immune landscape of EGFR-mutant LUAD at the single-cell level. Based on the results, many cellular components might have negative impact on the specific TME of EGFR-mutant LUAD through influencing CD8 TRM. Lack of CD8 TRM might be a key factor responsible for the suppressive TME of EGFR-mutant LUAD.
免疫疗法在表皮生长因子受体(EGFR)突变型非小细胞肺癌(NSCLC)患者中的疗效较低。据报道,较低的程序性死亡配体 1(PD-L1)表达和肿瘤突变负担(TMB)是其潜在机制。作为影响免疫疗法疗效的另一个重要因素,目前尚未全面了解这组 NSCLC 肿瘤微环境(TME)的特征。因此,我们开展了这项研究,从细胞组成和功能角度描述 EGFR 突变型肺腺癌(LUAD)的特定 TME,以更好地了解这种最常见的 NSCLC 亚型的免疫景观。
我们使用单细胞转录组测序和多重免疫组化技术研究 EGFR 突变型和 EGFR 野生型 LUAD 的免疫微环境,并确定免疫疗法的疗效。我们分析了 9 个未经治疗的样本中的单细胞,并使用生物信息学方法与之前从单细胞角度报道的 3 个免疫治疗后样本进行比较。
我们发现,EGFR 突变型恶性上皮细胞与无应答者的上皮细胞具有相似的特征。EGFR 突变型 LUAD 缺乏 CD8 组织驻留记忆(TRM)细胞,这些细胞可以通过分泌 CXCL13 促进三级淋巴结构的生成。此外,其他细胞类型,包括肿瘤相关巨噬细胞和癌症相关成纤维细胞,这些细胞能够在 TME 中募集、保留和扩增 CD8 TRM 细胞,在 EGFR 突变型 LUAD 中也缺乏。此外,与 EGFR 野生型 LUAD 相比,EGFR 突变型 LUAD 的 T 细胞与其他细胞类型之间通过程序性死亡-1(PD-1)和 PD-L1 或其他免疫检查点的相互作用明显减少。
我们的研究结果在单细胞水平上提供了对 EGFR 突变型 LUAD 免疫景观的全面理解。基于这些结果,许多细胞成分可能通过影响 CD8 TRM 对 EGFR 突变型 LUAD 的特定 TME 产生负面影响。缺乏 CD8 TRM 可能是导致 EGFR 突变型 LUAD 抑制性 TME 的关键因素。